

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/088 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/700,143
Sheet	1	Filing Date	November 3, 2003
	of 1	First Named Inventor	Robert M. Lorence
		Group Art Unit	1614
		Examiner Name	Not Assigned
		Attorney Docket Number	18029


NON PATENT PUBLICATIONS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
NK		Pecora, et al., "Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients with Advanced Solid Cancers", Journal of Clinical Oncology, Vol. 20, No. 9, May 1, 2002, pages 2251-2266.	
↓		Hotte, et al., "Prolonged Intravenous Infusion of PV701: Safety Profile and Objective Tumor Responses in a Phase a I Study of Advanced Cancer Patients", Oncolytic Viruses as Cancer Therapeutics, Scientific Program, Banff, Alberta, Canada, March 26-30, 2003, page 23. (Abstract)	
		Hotte, "Prolonged Intravenous Infusion of PV701: Safety Profile and Objective Tumor Responses in a Phase I Study", Oncolytic Viruses as Cancer Therapeutics, Scientific Program, Banff, Canada, March 28, 2003, pages 1-13. (Slide Presentation)	
		Lorence, et al., "Intravenous Administration of PV701, an Oncolytic Virus, in Phase I Studies: Novel Two-Step Advanced Cancer Patients", Eleventh International Conference on Gene Therapy of Cancer, San Diego, California, December 12-14, 2002, page S15-S16. (Abstract No. 039)	
		Lorence, et al., "Phase I Studies of Intravenous Administration of PV701, an Oncolytic Virus, in Patients with Advanced Solid Cancers", Eleventh International Conference on Gene Therapy of Cancer, San Diego, California, December 12, 2002, pages 1-18. (Slide Presentation)	
		Lorence, "Viruses for the Systemic Treatment of Cancer Patients", BioNorth 2002 Conference Program 9th Annual Ottawa Life Sciences International Conference and Exhibition, Ottawa Congress Centre, Ottawa, Ontario, Canada, November 4-6, 2002, page 70. (Session Abstract)	
↓		Lorence, "Viruses for the Systemic Treatment of Cancer Patients", BioNorth 2002 Conference Program, 9th Annual Ottawa Life Sciences International Conference and Exhibition, Ottawa Congress Centre, Ottawa, Ontario, Canada, November 6, 2002, pages 1-16. (Slide Presentation)	

Examiner Signature	/Nicole Kinsey/	Date Considered	09/01/2006
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible][illegible]

Examiner Signature	/Nicole Kinsey/	Date Considered	09/01/2006
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (08-03)